Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

74.13 -0.40 (-0.54%)
Official Closing Price Updated: 4:10 PM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
FDA Approves Bristol-Myers' Opdualag, First LAG-3-Blocking Antibody Combo, For Melanoma Patients
The  
Via Benzinga
Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session
From Bristol Myers Squibb
Via Business Wire
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
Why is Nektar Therapeutics (NKTR) Stock Down Today?
Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock? 
Via InvestorPlace
(BMY) - Analyzing Bristol-myers Squibb Company's Short Interest
Bristol-myers Squibb Company's (NYSE:BMY) short percent of float has risen 172.03% since its last report. The company recently reported that it has 70.88 million shares sold short... 
Via Benzinga
U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Markets Hold the Line after the Fed
Via Talk Markets
Why Eiger BioPharmaceuticals Stock Is Jumping Today
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to... 
Via Benzinga
Bristol-Myers Squibb And 2 Other Stocks Sold By Insiders
The Bank of England increased its key Bank Rate by 25bps to 0.75% during its recent meeting. Investors, meanwhile, focused on some notable insider trades When insiders sell shares... 
Via Benzinga
Top 3 Undervalued Dividend Growth Stocks in 2022
In turbulent times like what we are experiencing right now, blue-chip stocks that pay rising dividends can be a good choice. 
Via Talk Markets
7 Michael Burry Stocks to Buy as ‘The Big Short’ Investor Makes Moves
The famed investor has largely cashed out of equities, but you may want to check out these 7 Michael Burry stocks still in his portfolio. 
Via InvestorPlace
3 Top Stock Trades for This Week
Bulls seeking stock trades should focus on relative strength. Here are three stocks itching for new highs as the market sinks. 
Via InvestorPlace
Best Biotech Stocks To Buy In 2022
Biotechnology is the study of living creatures, biological systems, or derivatives to develop or improve healthcare products and therapies. This technology is connected with medical and... 
Via Talk Markets
Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit
Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of... 
Via Benzinga
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops
Sentiment was low heading into the study and analysts aren't hopeful for other tests. 
Via Investor's Business Daily
Why Nektar Therapeutics Shares Are Falling Today
Nektar Therapeutics (NASDAQ: NKTR) is trading significantly lower Monday morning after the company's Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (... 
Via Benzinga
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
From Bristol Myers Squibb
Via Business Wire
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Bristol Myers, Eli Lilly And 2 Others Prove You Can Still Make Money In Medical Stocks
These four medical stocks are outperforming the lousy market for health care investors. 
Via Investor's Business Daily
Pfizer's Newest Way To Rival Bristol Myers Squibb Might Surprise You
Pfizer is one of the leading drug stocks today, and it's planning to rival another, Bristol. 
Via Investor's Business Daily
7 Drug Stocks to Consider After the Viatris Plunge
As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market. 
Via InvestorPlace
What Stocks Does 'The Big Short' Investor Michael Burry Own?
Michael Burry is the founder and former hedge fund manager of now-defunct Scion Capital, most famously known for his massively profitable contrarian investment in the events... 
Via Benzinga
8 Strong Uptrend Stocks to Buy on the Next Dip
It's hard to believe, but there are uptrend stocks out there. Investors just have to look for the strength that these stocks are showing. 
Via InvestorPlace
7 Biotech Stocks With Key Catalysts in March
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. 
Via InvestorPlace
FDA Approves Bristol Myers' Opdivo Plus Chemo In Neoadjuvant Lung Cancer Setting
The FDA has approved Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for resectable non-small cell... 
Via Benzinga
Bristol-Myers Squibb Whale Trades For March 03
A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 11 strange trades. 
Via Benzinga
36 Stocks To Watch After Biden's First State of The Union Address
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
Via Benzinga
CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval
The FDA approved CTI BioPharma Corp's (NASDAQ: CTIC) Vonjo (pacritinib) for treating adult patients with myelofibrosis, a type of bone marrow cancer with low... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.